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Extended-release Naltrexone Economic Meta-Analysis 6 the comparative cost and utilization impact of medicated treatment with XR-NTX in patients with these disorders.
Materials and Methods
We searched MEDLINE and CINAHL (latest update on October 19, 2012) for observational and interventional studies using the following keyword search strategy:
"naltrexone" or "Vivitrol" or "extended-release naltrexone" AND "healthcare utilization" or "utilization" or "costs." Eligible studies evaluated one or more of these outcomes: medication adherence, service utilization (detoxification, inpatient, outpatient, ED), and healthcare expenditures in populations being treated for alcohol or opioid dependence disorders. Studies were excluded if they did not specifically compare XR-NTX to one or more substance abuse medications for one or more of the outcomes described above.
We extracted the results into an evidence table including author, population studied, year of publication, treatments evaluated, inclusion and exclusion criteria, number of subjects screened and enrolled, age, sex, disease severity, analytic method, confounder adjustment, outpatient utilization, inpatient utilization, medication adherence, inpatient costs and study quality. We rated study quality on three domains using the Newcastle-Ottawa Scale (NOS) quality assessment tool (Wells et al.) . The NOS is a rating scale to evaluate the quality of observational research -higher scores reflect better quality. Studies receive up to 9 points distributed among 3 domains: exposure selection (4 points), comparability of comparison groups (2 points) and outcome assessments (3 points).
Outcomes were predominately continuous and differences between treatment regimens were explored using random-effects meta-analysis. For similar but non-identical outcome variables, we pooled the standardized mean difference (SMD) using Hedge's g to estimate effect
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Extended-release Naltrexone Economic Meta-Analysis 7 sizes (0.2 represents a small effect, 0.5 is a moderate effect, and 0.8 is a large effect) (Cohen, 1988) . We calculated unreported standard deviations based on reported p-values or 95%
confidence intervals using established methods (J. Higgins & Green, 2011) . Statistical heterogeneity was explored both qualitatively, through comparison of study population settings, treatments, and methodology, and quantitatively using the I 2 statistic and selected sensitivity analyses (J. P. Higgins & Thompson, 2002) . The I 2 statistic is used in meta-analyses to quantify the proportion of total variation among studies that is due to heterogeneity rather than chance. If significant heterogeneity was present, we qualitatively assessed the component studies and excluded specific studies to evaluate the impact on results. We did not conduct formal analyses for publication bias because of the small number of studies identified (Sterne et al., 2011) . All statistical analyses were conducted using Stata/IC 11.0 (StataCorp LP, College Station TX).
Results

Study Selection
Figure 1 summarizes the study search and study selection results. The keyword literature search found 111 study citations. After screening abstracts, we retrieved full text for 11 studies deemed to be germane to our synthesis. No interventional studies and five observational studies met inclusion criteria (Baser, Chalk, Fiellin, & Gastfriend, 2011; Baser, Chalk, Rawson, & Gastfriend, 2011; Bryson, McConnell, Korthuis, & McCarty, 2011; Harris et al., 2012; Mark, Montejano, Kranzler, Chalk, & Gastfriend, 2010) . Table 1 summarizes key study characteristics and study results. Four studies were retrospective cohort studies using administrative claims data from commercial health plans (Baser, Chalk, Fiellin, et al., 2011; Baser, Chalk, Rawson, et al., 2011; Bryson et al., 2011; Mark et al., 2010) . Three studies (two in alcohol dependence and one in opioid dependence) compared patients receiving any pharmacotherapy to unmedicated
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Extended-release Naltrexone Economic Meta-Analysis 8 patients (Baser, Chalk, Fiellin, et al., 2011; Baser, Chalk, Rawson, et al., 2011; Mark et al., 2010) . Four studies compared the impact of XR-NTX versus other agents, using differing analytic approaches with a variety of healthcare and medication utilization outcomes over 6 months. A fifth study, based on administrative data from the Veterans Health Administration (VHA), assessed adherence in patients using XR-NTX, NTX-PO, acamprosate or disulfiram for alcohol abuse (Harris et al., 2012) . Four studies examined alcohol dependence (Baser, Chalk, Rawson, et al., 2011; Bryson et al., 2011; Harris et al., 2012; Mark et al., 2010) , and one examined opioid dependence (Baser, Chalk, Fiellin, et al., 2011) .
Studies represented a mixture of both manufacturer-sponsored (Baser, Chalk, Fiellin, et al., 2011; Baser, Chalk, Rawson, et al., 2011; Mark et al., 2010) and independent research (Bryson et al., 2011; Harris et al., 2012) . The NOS scores were comparable across the five studies and ranged from 7 to 8 out of 9 total points. All but one study used a variety of statistical approaches to control for confounding and baseline imbalance: two studies of alcohol dependent patients used propensity score (Baser, Chalk, Rawson, et al., 2011; Mark et al., 2010 ) and the opioid dependence study used instrumental variable analysis (Baser, Chalk, Fiellin, et al., 2011) .
Covariates considered for adjustment were generally comprehensive and included key demographics, psychiatric diagnoses, comorbidity scores (e.g. Deyo-Charlson) and baseline healthcare utilization. One analysis used difference-in-differences analysis with adjustment for demographic variables but not comorbidities (Bryson et al., 2011) . The VA study did not statistically adjust measures of adherence using baseline comorbidity variables (Harris et al., 2012) .
Medication Refill Persistence
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Five studies examined medication adherence and reported the proportion of days covered (PDC) or a similar value measuring the ratio of days' supply dispensed to total days in the observation period (180 days) (Baser, Chalk, Fiellin, et al., 2011; Baser, Chalk, Rawson, et al., 2011; Bryson et al., 2011; Harris et al., 2012; Mark et al., 2010) . For one study, we were able to obtain total days' supply dispensed for each drug from a co-author (Bryson et al., 2011) . Figure   2 shows the pooled differences in the numbers of days covered by medication for XR-NTX versus comparators, by study population. Among the alcohol dependence studies, XR-NTX was consistently associated with longer medication persistence compared to oral agents, from 9.4 days longer (95% CI 4.3 -14.5) versus NTX-PO to 15.9 days (95% CI 10.0 -21.8) versus
acamprosate. Compared to disulfiram, the greater mean duration with XR-NTX did not reach significance, however heterogeneity was quite high. In opioid dependence, XR-NTX was not associated with significant differences in medication days covered relative to any comparator.
Detoxification Facility Use
Three studies analyzed inpatient detoxification facility utilization during the six months following the initial treatment (Baser, Chalk, Fiellin, et al., 2011; Baser, Chalk, Rawson, et al., 2011; Mark et al., 2010) . In alcohol dependence, Figure 3 suggests that XR-NTX was associated with significant reductions of 201 fewer days/1000 patients (95% CI -6 --396) in detoxification facilities versus disulfiram and 487 fewer days/1000 patients (95% CI -161 --814) versus acamprosate. With opioid dependence agents, however, differences in days of detoxification were not significant.
Substance-abuse Related Inpatient Utilization
Four studies reported inpatient utilization for alcohol or opioid dependence (Baser, Chalk, Fiellin, et al., 2011; Baser, Chalk, Rawson, et al., 2011; Bryson et al., 2011; Mark et al., A C C E P T E D M A N U S C R I P T
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Extended-release Naltrexone Economic Meta-Analysis 10 2010) but one analysis did not differentiate substance-related (e.g., for alcoholic pancreatitis or infectious cellulitis) versus unrelated inpatient utilization (e.g., possibly substance related but not coded as such) (Bryson et al., 2011) and one reported only inpatient days while the others reported admissions (Mark et al., 2010) . To manage these differences, we pooled the SMD in inpatient utilization (admission or inpatient days) across studies. As shown in Figure 
Emergency Department Utilization
Four studies reported ED visits (Baser, Chalk, Fiellin, et al., 2011; Baser, Chalk, Rawson, et al., 2011; Bryson et al., 2011; Mark et al., 2010) . Because the study by Mark and colleagues (Mark et al., 2010) only reported alcohol-related ED utilization, we calculated the SMD for each study. In studies of alcohol dependent patients we found no significant differences in ED utilization for XR-NTX versus other agents. In the opioid study, XR-NTX was associated with a 982 visit reduction/1000 patients (p < 0.0001) versus methadone, corresponding to a 0.32 reduction in SMD (95% CI -0.08 --0.01).
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Total Costs
Two papers reported the total of all inpatient, outpatient, addiction specialty, medical and pharmaceutical costs during the six months post index treatment (Baser, Chalk, Fiellin, et al., 2011; Baser, Chalk, Rawson, et al., 2011) and a third examined total costs excluding pharmacy (Bryson et al., 2011) . Figure 5 shows the forest plot for a meta-analysis on total cost. In no comparison was XR-NTX associated with significantly greater overall healthcare costs. In the two alcohol dependence studies, XR-NTX patients had lower total cost versus acamprosate (-$2729; 95% CI -$4482 --$976). Excluding the Bryson et al. data (Bryson et al., 2011) did not substantially alter the result (-$3588; 95% CI -$5396 --$1780). In opioid dependence, XR-NTX patients had significantly lower total costs versus methadone (-$8170; 95% CI -12286 --4054). Table 2 summarizes pooled estimates from these studies along with a transformation into more clinically meaningful metrics. The cost and utilization estimates were rescaled to reflect the number of patients required to be treated with XR-NTX over the alternative medication in order to achieve a particular reduction. We converted the inpatient substance abuse-related SMD to days/per 1000 patients by multiplying the pooled estimate by the pooled standard deviation (5935), which was calculated from data provided by Mark and colleagues for XR-NTX (Mark et al., 2010) . These data suggest that a 30 day reduction in detoxification facility utilization can be achieved by treating between 62 and 149 patients with XR-NTX instead of acamprosate or disulfiram respectively. Similarly, we estimate that treating as few as 14 patients with XR-NTX instead of acamprosate or 68 patients instead of NTX-PO will avoid $10,000 in spending for substance abuse-related inpatient care. Only 4 additional patients would need to be treated with
Conversion to Clinical Metrics
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Medication versus No Medication
Three of the studies pooled patients taking any medication and compared them with patients who received treatment for a substance dependence diagnosis but without an approved pharmaceutical (Baser, Chalk, Fiellin, et al., 2011; Baser, Chalk, Rawson, et al., 2011; Mark et al., 2010) . Bryson and colleagues (Bryson et al., 2011 ) compared patients receiving XR-NTX to those who received psychosocial treatment, in particular, and the study was included in sensitivity analyses. Across three studies, treatment with any medication was associated with 2594 fewer days (per 1000 patients) of detoxification facility use (95% CI 580 -4609, I 2 =100%) over a six month period. Heterogeneity was very high, as estimates varied widely from study to study. In alcohol dependence, medication was associated with significant reductions in detoxification facility use (per 1000 patients) that ranged from 457 fewer days (95% CI 252 -662) to 3014 fewer days (95% CI 2866 -3162) versus non-medicated care. In opioid dependence (Baser, Chalk, Fiellin, et al., 2011) , medication was associated with 4311 fewer days (95% CI 4115 -4507) in detoxification facility use (per 1000 patients). We used SMD to combine inpatient substance abuse admissions or days among the three reporting studies (Baser, Chalk, Fiellin, et al., 2011; Baser, Chalk, Rawson, et al., 2011; Mark et al., 2010) . 
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Extended-release Naltrexone Economic Meta-Analysis 13 0.85) (Baser, Chalk, Fiellin, et al., 2011) . Three studies reported total costs for any medication versus none (Baser, Chalk, Fiellin, et al., 2011; Baser, Chalk, Rawson, et al., 2011; Mark et al., 2010 ) and the Bryson study (Bryson et al., 2011) reported total non-pharmacy costs for XR-NTX versus no medication. Overall, total costs were lower by an average of $3649 (95% CI $3181 -$4117; I 2 =18%) in patients receiving a medication versus those who did not. Removing the Bryson data did not substantially affect this estimate.
Discussion
The meta-analysis suggests among the approved pharmacotherapies, alcohol dependent XR-NTX patients had as low or lower healthcare costs, with the longest medication persistence and the least inpatient utilization. Although prior work described the efficacy of oral agents as inconsistent and modest (Pettinati et al., 2006) , our analyses, in contrast, show relatively consistent cost and utilization reductions associated with use of XR-NTX. Our findings generally coincide with another study examining the association between oral naltrexone persistence and reduced healthcare service utilization (Kranzler et al., 2008) . Although not the primary aim of this study, we found that alcohol or opioid dependent patients who do not receive an approved pharmacotherapy experience higher six-month healthcare costs and more hospitalization.
In opioid dependence, XR-NTX patients also had similar or lower costs and less substance-related inpatient utilization than patients treated with other agents. Statistical power, however, may have been limited given the availability of only a single opioid dependence study and a relatively smaller number of patients treated with XR-NTX (n=156). The generally positive XR-NTX effects for opioid dependence may be unexpected because the standard of care has been agonist medications. Many patients reluctant to initiate agonist therapy, however, may
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Extended-release Naltrexone Economic Meta-Analysis 14 find a long-acting opioid antagonist useful in the course of recovery. Additional utilization analyses in opioid dependence are required to fully assess the relative advantages and disadvantages of agonist and antagonist therapy, and the optimal duration of treatment. Benefit from opioid substitution treatment is expected when treatment extends beyond one year (Cornish, Macleod, Strang, Vickerman, & Hickman, 2010) , however, the Baser study of opioid dependence agents found a substantially shorter mean duration (Baser, Chalk, Fiellin, et al., 2011) . Meanwhile, the optimal duration with extended antagonist therapy has not been specified and remains an individualized clinical decision.
Limitations and Strengths
Limitations of these studies include the use of slightly different outcome measures, although we used a SMD approach to accommodate the variation. Patients were not randomly assigned, leaving the potential for residual confounding (Schneeweiss & Avorn, 2005) , although these studies employed rigorous controls for pre-treatment patient variation. Comparisons between medication treatment and no medication treatment could be particularly problematic because of significant unmeasured differences in severity of illness. Four of five studies reflect a commercially insured population which may limit generalizability. Research from publically funded healthcare programs would be helpful for establishing the comparative benefits of XR-NTX for those of lower socio-economic status who are disproportionally affected by substance abuse disorders.
In light of the approaching coverage expansion as part of the Affordable Care Act, similar studies conducted within state Medicaid programs are needed. The small number of eligible studies reflects the relatively recent approval of XR-NTX for alcohol and opioid use disorders. The follow-up in all five studies was limited to six months and it remains unclear if
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Extended-release Naltrexone Economic Meta-Analysis 15 effects are sustained beyond the study period. The ultimate duration of treatment for opioid and alcohol use disorders remains uncertain because clinical trial data for XR-NTX is limited to 12 to 24 weeks in duration. The opioid dependence data require replication because they are based on one study with data collected prior to FDA approval of XR-NTX for opioid dependence treatment. Although we summarize the aggregate medication versus no-medication comparisons presented in three of the studies, these results must be viewed as exploratory because the primary goal and search was for studies examining treatment with XR-NTX. Treatment effect for medication versus no medication comparisons appear to be quite large, especially when compared to individual drug effects, however heterogeneity between the studies was high and pooled estimates may not be reliable. Finally, because we only found five relevant studies, our findings could be altered by any unpublished negative studies.
Despite these limitations, comparative research using retrospective database analysis provides effectiveness data, addresses broader populations than efficacy trials, and has increased policy relevance (Institute of Medicine, 2009). Our analysis used real-world data from naturalistic community treatment, and included nearly 60,000 patients receiving medication and 1,565 receiving XR-NTX, making it the only comprehensive analysis across all approved substance-dependence pharmacotherapies, to date. The analyses using multiple data sets found generally consistent results across a diversity of payers despite variability in benefits covered, patient populations and case-mix control methods.
We encourage continued analyses of healthcare utilization data. States have begun to build All-Payer All-Claims data bases and such data could provide comprehensive analyses across commercial and public health plans. Subsequent analyses should include public insurance data, track longer durations of treatment and post-treatment, and elucidate patient characteristics
Extended-release Naltrexone Economic Meta-Analysis 16 and treatment patterns that predict optimal health economic outcomes and patient benefit. Also, the evidence base could benefit from a larger study of XR-NTX in opioid dependence.
Finally, given the lack of meaningful adoption of pharmacotherapy in addiction treatment, general medicine physicians, hospitals, insurers and policymakers need to explore innovative means of fostering such growth, including disease management and integration with general medical care. Clinical trials document the efficacy of pharmacotherapy (Mattick, Breen, Kimber, & Davoli, 2009; Mattick, Kimber, Breen, & Davoli, 2008; Rösner et al., 2010) and FDA-approved medications are available. National consensus standards, moreover, recommend pharmacotherapy (National Quality Forum, 2007) and both alcohol and opioid dependence can be successfully addressed in primary care settings (Sullivan, Tetrault, Braithwaite, Turner, & Fiellin, 2011) . Finally, physicians have used XR-NTX successfully in both hospital and community-based general internal medicine practices (Lee et al., 2010) .
Nonetheless, antipathy and ambivalence toward the use of medications to support recovery from alcohol and opioid dependence persist and reflect biases in philosophy of care, limited access to prescribers, a lack of training among prescribers and counselors, financing and licensing policies that inhibit use of medications, and perceptions that the cost of the medications is excessive (Knudsen, Abraham & Oser, 2011) . The current average wholesale price of XR-NTX ($1320 for one monthly injection; the Medicaid price is about 50% of the commercial price) constrains use. Other medications used for substance use disorders, however, are available generically and the relative high cost of XR-NTX may inhibit adoption for healthcare systems.
Although the acquisition costs of XR-NTX are substantially higher than that of other agents, the evidence reviewed suggests off-setting reductions in other healthcare utilization producing either no net increase or reduced total costs of care. The reductions in costs and utilization found in the
Extended-release Naltrexone Economic Meta-Analysis 17 present study with medication, and in particular with XR-NTX, may be relevant for accountable care organizations or patient-centered medical home models. Given rising pressures to reduce potentially preventable hospital readmissions and other reducible cost and morbidity causes, the optimization of patient care and management of resources warrant systemic change in the delivery of addiction treatment in the advancing era of health care reform.
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